Meeting
2024 ASCO Annual Meeting
The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.
Authors
Zac Coyne
Princess Margaret Cancer Centre, Toronto, ON, Canada
Zac Coyne , Rinku Sutradhar , Vivian Aghanya , Yosuf Kaliwal , Yue Niu , Ning Liu , Ying Liu , Melanie Lynn Powis , Geoffrey Liu , Jeffrey M. Peppercorn , Monika K. Krzyzanowska , Lawson Eng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptom Science and Palliative Care
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 12041)
DOI
10.1200/JCO.2024.42.16_suppl.12041
Abstract #
12041
Poster Bd #
170
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
First Author: Paul Lorigan
Poster
2023 ASCO Annual Meeting
Melanomas lacking HLA class I expression and response to checkpoint inhibitor.
First Author: Paul B. Chapman
Poster
2023 ASCO Annual Meeting
The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.
First Author: Elizabeth Faour
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane